CRISPR Therapeutics AG
CRSPFigures shown here come from public SEC filings. Dates beside each section show the available history.
How CRISPR Therapeutics AG Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 12 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 9, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Twin Lakes Capital Management, LLC | 2026-03-31 | 682 | $32.4K | SEC filing |
| IVC Wealth Advisors LLC | 2026-03-31 | 5,055 | $240K | SEC filing |
| NWAM LLC | 2026-03-31 | 9,173 | $436K | SEC filing |
| Clearstead Advisors, LLC | 2026-03-31 | 75 | $3.57K | SEC filing |
| BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC | 2026-03-31 | 101 | $4.81K | SEC filing |
| VALLEY WEALTH MANAGERS, INC. | 2026-03-31 | 0 | $11 | SEC filing |
| Larson Financial Group LLC | 2026-03-31 | 1,338 | $63.6K | SEC filing |
| KESTRA PRIVATE WEALTH SERVICES, LLC | 2026-03-31 | 11,064 | $526K | SEC filing |
| Swiss National Bank | 2026-03-31 | 169,700 | $8.07M | SEC filing |
| Pacifica Partners Inc. | 2026-03-31 | 30 | $1.43K | SEC filing |
| Atlantic Private Wealth, LLC | 2026-03-31 | 15 | $714 | SEC filing |
| MONEY CONCEPTS CAPITAL CORP | 2026-03-31 | 4,738 | $225K | SEC filing |
| D.A. DAVIDSON & CO. | 2026-03-31 | 6,324 | $301K | SEC filing |
| Archer Investment Corp | 2026-03-31 | 20 | $951 | SEC filing |
| Versant Capital Management, Inc | 2026-03-31 | 169 | $8.04K | SEC filing |
| Curi Capital, LLC | 2026-03-31 | 49,706 | $2.36M | SEC filing |
| ARK Investment Management LLC | 2026-03-31 | 11,313,623 | $538M | SEC filing |
| ALPINE WOODS CAPITAL INVESTORS, LLC | 2026-03-31 | 8,220 | $391K | SEC filing |
| HIGHLINE WEALTH PARTNERS LLC | 2026-03-31 | 1,000 | $47.6K | SEC filing |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 2026-03-31 | 21,519 | $1.02M | SEC filing |
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among CRISPR Therapeutics AG's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-01-22 · Kulkarni Samarth: Larger than all 64 other insider sales of Common Shares on file. SEC filing
- 2026-01-22 · Prasad Raju: Larger than 62 of the 64 other insider sales of Common Shares on file. SEC filing
- 2026-01-20 · Kulkarni Samarth: Larger than 60 of the 64 other insider sales of Common Shares on file. SEC filing
- 2026-01-06 · Prasad Raju: Larger than 59 of the 64 other insider sales of Common Shares on file. SEC filing
- 2025-10-17 · Kulkarni Samarth: Larger than 63 of the 64 other insider sales of Common Shares on file. SEC filing
- 2024-11-11 · Kulkarni Samarth: Larger than 61 of the 64 other insider sales of Common Shares on file. SEC filing
- 2024-04-15 · Kulkarni Samarth: Larger than 58 of the 64 other insider sales of Common Shares on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-29 | Patel Naimish · Chief Medical Officer | Common Shares | S — Open market or private sale | −3,786 | 55.62 | SEC filing |
| 2026-03-23 | Kulkarni Samarth · Chief Executive Officer | Common Shares | S — Open market or private sale | −10,020 | 46.78 | SEC filing |
| 2026-03-23 | KASINGER JAMES R. · General Counsel and Secretary | Common Shares | S — Open market or private sale | −3,182 | 46.78 | SEC filing |
| 2026-03-23 | Prasad Raju · Chief Financial Officer | Common Shares | S — Open market or private sale | −3,708 | 46.78 | SEC filing |
| 2026-03-16 | Patel Naimish · Chief Medical Officer | Common Shares | S — Open market or private sale | −3,150 | 48.26 | SEC filing |
| 2026-03-16 | Prasad Raju · Chief Financial Officer | Common Shares | S — Open market or private sale | −4,021 | 48.26 | SEC filing |
| 2026-03-16 | Kulkarni Samarth · Chief Executive Officer | Common Shares | S — Open market or private sale | −10,349 | 48.26 | SEC filing |
| 2026-03-16 | KASINGER JAMES R. · General Counsel and Secretary | Common Shares | S — Open market or private sale | −3,450 | 48.26 | SEC filing |
Showing 8 of 16 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-05 | Greene John · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +13,000 | SEC filing |
| 2026-06-05 | Treco Douglas A · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +13,000 | SEC filing |
| 2026-06-05 | Fleming Harold Edward · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +13,000 | SEC filing |
| 2026-06-05 | Fardis Maria · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +13,000 | SEC filing |
| 2026-06-05 | Rommel Christian · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +13,000 | SEC filing |
| 2026-06-05 | George Simeon · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +13,000 | SEC filing |
| 2026-06-05 | High Katherine A · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +13,000 | SEC filing |
| 2026-06-05 | Behbahani Ali · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +13,000 | SEC filing |
Showing 8 of 24 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.